Tully KH, Cone EB, Cole AP, et al. - This study draws on data from the Surveillance, Epidemiology, and End Results cancer registries and linked Medicare claims between January 2010 and December 2015 to investigate the risk of immune-related adverse events (irAEs) in patients with a preexisting autoimmune disease (pAID) presenting with a cutaneous melanoma receiving an immune checkpoint inhibitor (ICI) therapy. Patients diagnosed with cutaneous melanoma who had pAID or received ICI or both were identified. A total of 3,704 people were involved in the analysis. Patients who have a pAID are at a significantly higher risk of developing irAEs.